FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol Frigolé4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins Martinho10, Camillo Ribi11, Matthieu Groh12, Benjamin Terrier13. | 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; 2Sechenov University, Moscow, Russia; 3University of Padova, Padova, Italy; 4Hospital Clinic, University of Barcelona, Barcelona, Spain; 5University of Alberta, Edmonton, Canada; 6CHU Estaing Clermont-Ferrand France; 7Toulouse University Toulouse France; 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 9Medius Kliniken Kirchheim-Teck Germany; 10ULS Santa Maria, Lisbon, Portugal; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Hopital Foch, Suresnes, France; 13Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.
330 -
PO:14:199 | Preliminary data of a multicentric study on safety and efficacy of assisted reproductive techniques in pregnant women with systemic autoimmune diseases Valentina Canti1, Maria Bernadette Cilona1, Giuditta Gorgone1, Federica Pasi1, Antonia Calligaro2, Francesca Ruffilli3, Francesca Crisafulli6, Maria Tonello2, Eleonora Giacobbe4, Alba Chiara Pozzi6, Maria Chiara Gerardi4, Melissa Padovan3, Emanuele Bizzi5, Enrico Papaleo1, Beatrice Maranini3, Marcello Govoni3, Massimiliano Epis4, Angela Tincani6, Andrea Doria2, Patrizia Rovere Querini1 | 1IRCCS Ospedale San Raffaele and VitaSalute San Raffaele Milano, Italy; 2Rheumatology Unit, Departement of Medicine, University Hospital of Padua Padova, Italy; 3Rheumatology Unit, Azienda Ospedaliero Universitaria S. Anna Ferrara, Department of Medical Sciences, University of Fe Ferrara, Italy; 4ASST Grande Ospedale Metropolitano Niguarda Milano, Italy; 5Internal Medicine, Fatebenefratelli Hospital Milano, Italy; 6Rheumatology and Immunology Unit, ASST Spedali Civili Brescia e Università degli Studi di Brescia, Italy
85 -
PO:15:216 | Safety and Efficacy of a single dose of Rituximab to manage Pregnancy-Related Severe Flare of Systemic Lupus Erythematosus: A Case Report Eugenio Capparelli1, Daniela Bompane1, Eleonora Zaccara1, Laura Castelnovo1, Antonio Tamburello1, Antonino Mazzone2, Paola Faggioli1 | 1UOC Reumatologia, ASST Ovest Milanese, Legnano, Milano, Italy; 2UOC Medicina Interna, ASST Ovest Milanese, Legnano, Milano, Italy
188 -
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a post-hoc summary of five phase 3 trials Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Hn Harris4, Ciara O'Shea5, Roger A. Levy6, Andrea Doria7 | 1Centro Accademico Reumatologia, Dipartimento Scienze Cliniche Biologiche, Università degli Studi Torino, Osp. Mauriziano, Italy; 2Brigham and Women's Hospital, Divisione di Reumatologia, Infiammazione e Immunità, Harvard Medical School, Boston, MA, USA; 3Università Johannes Gutenberg di Mainz, Centro medico universitario, Germany; 4GSK, Immunologia Biostatistica London, UK; 5GSK, Global Medical Affairs Reumatologia, Dublin, Ireland; 6GSK, Global Medical Affairs Collegeville, PA, USA; 7Divisione di Reumatologia, Dipartimento di Medicina, Università di Padova, Italy
259 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
190 -
PO:29:138 | Cetylated fatty acids and fibromyalgia: efficacy and tolerability in a prospective study Anna Capogna1, Marco Bardelli1, Luca Cantarini1, Bruno Frediani1 | 1UOC Reumatologia, Dipartimento di Scienze mediche, chirurgiche e neuroscienze, Università degli Studi di Siena, Italy
263 -
PO:03:033 | Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine/Rheumatology, University of California San Francisco, USA; 6UCB Monheim am Rhein Germany; 7UCB Braine-lAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany
110 -
PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.
252 -
Treatment of Wegener’s granulomatosis
1554Downloads: 5392 -
PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano1, Davide Gaspare Patti1, Valentina Boni1, Stefano Di Murro1, Cesare Gavotti1, Roberta Masnata1, Giulia Calabrese2, Gerlando Natalello2, Giusy Peluso2, Augusta Ortolan1|2, Enrico De Lorenzis1|2, Maria Antonietta D'Agostino1|2. | 1Università Cattolica del Sacro Cuore, Roma, Italy; 2Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
257 -
PO:35:223 | Biologic therapy for sustained remission in eosinophilic myocarditis: real-world evidence from a tertiary center experience Federica Davanzo1, Caterina Menghi2, Andrea Silvio Giordani2, Anna Baritussio2, Federico Scognamiglio2, Cristina Vicenzetto2, Luca Iorio1, Renzo Marcolongo2, Cristina Basso3, Andrea Doria1, Roberto Padoan1, Alida Linda Patr Caforio2 | 1Rheumatology Unit, Department of Medicine, University of Padua Padova, Italy; 2Cardiology Unit, Department of Cardiac, Vascular, Thoracic Sciences and Public Health, University of Padua Padova, Italy; 3Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua Padova, Italy
102 -
PO:17:248 | Prevention of human papillomavirus infection in women with systemic lupus erythematosus: a single-center cross-sectional study Clizia Gagliardi1, Maria Chiara Gerardi1, Bianca Lucia Palermo1, Giulia Carrea1, Maria Di Cicco1, Elena Manna1, Giulia Segatto1, Antonella Adinolfi1, Laura Belloli1, Cinzia Casu1, Silvia Cavalli1, Davide Antonio Filippini1, Matteo Longhi1, Gabriella Maioli1, Martina Schettino1, Nicola Ughi1, Elisa Verduci1, Arianna Bertolucci1, Lara Buffa1, Giulia Buonsante1, Claudia Cordini1, Eleonora Giacobbe1, Francesco Molica Colella1, Oscar Epis1 | 1ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
268 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
84 -
PO:17:259 | Anifrolumab: a new management of SLE Giorgia Montozzi1, Chiara Cocco1, Ramona Santangeli1, Lucia Gamba1, Paola Fioretti1, Letizia Curina1, Chiara Guidoni1, Edoardo Cipolletta3, Gianluca Moroncini2 | 1Scuola di Specializzazione in Medicina Interna, Università Politecnica delle Marche Ancona, Italy; 2Department of Clinical and Molecular Sciences, Università Politecnica delle Marche Ancona, Italy; 3Rheumatology Unit, Department of Clinical and Molecular Sciences , Università Politecnica delle Marche Ancona, Italy
194 -
PO:06:078 | Is difficult-to-treat rheumatoid arthritis less severe in patients with autoantibody-negative disease? retrospective analysis from a monocentric cohort. Bernardo D'Onofrio1, Maria Chiara Ditto1, Francesco Ghellere1, Giacomo Tanti1, Salvatore Panaro1, Enrico Fusaro1, Simone Parisi1. | 1AOU Città della Salute e della Scienza, Torino, Italy.
215 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
76 -
PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi1, Fulvia Ceccarelli2, Fabio Leo3, Paola Roccatagliata3, Chiara Tani4, Margherita Zen5 | 1Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; 2Unità di Reumatologia, Università Sapienza Roma Italy; 3AstraZeneca S.p.a. Milano Italy; 4Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; 5Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy
205 -
Safety of rituximab in rheumatoid arthritis
1975Downloads: 1157 -
CO:09:6 | Risk of disease flare during pregnancy and postpartum in inflammatory arthritis: association with therapy discontinuation in the prospective P-RHEUM.it study Dina Zucchi1, Chiara Tani1, Francesca Crisafulli2, Alessia Gatti2, Maria Gerosa3, Cecilia Chighizola3, Melissa Padovan4, Salvatore D'Angelo5, Florenzo Iannone6, Maria Sole Chimenti7, Claudia Lomater8, Francesca Serale9, Veronique Ramoni10, Oscar Epis11, Bernd Raffeiner12, Ariela Hoxha13, Andrea Doria14, Leonardo Santo15, Valentina Canti16, Francesca Bellisai17, Giovanna Cuomo18, on behalf of the P-Rheumit Investigators19, Greta Carrara20, Cristina Di Nicola20, Davide Rozza20, Carlo Alberto Scirè20, Maria Chiara Gerardi11, Angela Tincani2, Laura Andreoli2, Marta Mosca1. | 1Rheumatology Unit, University of Pisa and Azienda Ospedaliero Universitaria Pisana; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia; 3Clinical Rheumatology Division, ASST Gaetano Pini-CTO and University of Milano; 4Rheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna and University of Ferrara; 5Rheumatology Department of Lucania - San Carlo Hospital, Potenza; 6Rheumatology Unit, DiMePRE-J, University of Bari; 7Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome-Tor Vergata, Roma; 8Torino Academic Rheumatology Center, A.O. Mauriziano di Torino, University of Torino; 9Rheumatology Unit, ASL CN1 Cuneo; 10Internal Medicine Department, ASST Lodi - Ospedale Maggiore di Lodi; 11Division of Rheumatology, Multispecialist Medical Department, Grande Ospedale Metropolitano Niguarda, Milano; 12Department of Rheumatology, Central Hospital of Bolzano SABES-ASDAA, Bolzano; 13General Medicine and Thrombosis and Hemorrhagic Unit, Department of Medicine, University of Padova; 14Rheumatology Unit, Department of Medicine, University of Padova; 15Rheumatology Unit, Mons. Dimiccoli Hospital, Barletta; 16Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano; 17Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena; 18Precision Medicine Department, University of Campania L. Vanvitelli, Napoli; 19The Italian Society for Rheumatology; 20Epidemiology Research Unit of the Italian Society for Rheumatology, Milano, Italy
336 -
PO:25:079 | Anifrolumab in refractory dermatomyositis: a case report Chiara Calabrese1, Corrado Campochiaro1|2, Giacomo De Luca 1|2, Veronica Batani1, Marco Matucci-Cerinic1|2, Lorenzo Dagna 1|2 | 1Dipartimento di Reumatologia e Scienze Mediche, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO Milano; 2Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e Trapianti, Milano, Italy
255 -
PO:06:089 | Heat-not-burn cigarettes induce protein post-translational modifications (PTM): possible role in the pathogenesis of rheumatoid arthritis Claudia Ciancarella1, Federica Maria Ucci1, Valeria Manganelli2, Elena Fasciolo2, Roberta Priori1, Fulvia Ceccarelli1, Manuel Sergi3, Camilla Montesano3, Francesco Bartolini3, Maurizio Sorice2, Cristiano Alessandri1, Fabrizio Conti1 | 1Rheumatology Unit, Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, La Sapienza, Roma, Italy; 2Department of Experimental Medicine, La Sapienza University of Rome, Italy; 3Department of Chemistry, La Sapienza University Of Rome, Italy
115 -
PO:17:255 | Efficacy and safety of voclosporin in the management of lupus nephritis: a case series Alessandra Oliva1, Elisabetta Chessa2, Marta Paola Pireddu1, Marianna Salis1, Giulia Rizzo1, Fabio Congiu1, Elena Ragusa1, Antonello Pani3|4, Alberto Cauli1|2, Nicola Lepori3|4, Matteo Piga1|2 | 1UOC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università degli Studi di Cagliari; 2UOC Reumatologia, AOU Cagliari; 3SC Nefrologia e Dialisi, Università degli Studi di Cagliari; 4SC Nefrologia e Dialisi, Azienda Ospedaliera Brotzu, Cagliari, Italy
259 -
PO:16:225 | Belimumab in refractory and/or non-criteria manifestations of antiphospholipid syndrome: ad interim analysis on Quality-of-Life changes from the BLAST trial Alessio Conti1, Lois Ira Capulong1, Irene Cecchi1, Elena Rubini1, Chiara Bova1, Massimo Radin1, Alice Barinotti1, Beatrice Ala1, Silvia Grazietta Foddai1, Daniela Rossi1, Roberta Fenoglio1, Savino Sciascia1 | 1Centro di Eccellenza Universitario per le Malattie Nefrologiche, Reumatologiche e Rare, S.G.Bosco -ASL Città di Torino, Italy
96 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
305 -
PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
361
